Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

McKesson
Fuji
Cipla
Daiichi Sankyo
Teva
Dow
Baxter
US Department of Justice
Deloitte

Generated: December 12, 2018

DrugPatentWatch Database Preview

Litigation Details for Novartis AG v. Actavis Elizabeth LLC (D. Del. 2014)

« Back to Dashboard

Novartis AG v. Actavis Elizabeth LLC (D. Del. 2014)

Docket ➤ Sign Up Date Filed 2014-12-16
Court District Court, D. Delaware Date Terminated 2017-06-09
Cause 35:145 Patent Infringement Assigned To Leonard Philip Stark
Jury Demand None Referred To
Parties ACTAVIS ELIZABETH LLC; ACTAVIS INC.; APOTEX CORP.; APOTEX INC.; EZRA VENTURES LLC; HEC PHARM CO. LTD.; HEC PHARM GROUP; HEC PHARM USA INC.; MITSUBISHI TANABE PHARMA CORPORATION; MITSUI SUGAR CO. LTD.; NOVARTIS AG; NOVARTIS PHARMACEUTICALS CORPORATION
Patents 5,604,229
Attorneys Aya Cieslak-Tochigi; Benjamin A. Smyth; Bindu Ann George Palapura; Brian Kwok; Daniel M. Silver; David Ellis Moore; Dennis D. Gregory; James A. Shimota; Joseph E. Cwik; Mary Procaccio-Flowers; Melanie K. Sharp; Michael P. Kelly; Michael Siem; Robert M. Vrana; Sami Sedghani; Shashank T. Upadhye; Stamatios Stamoulis; Steven R Daniels; Tung-On Kong; Yongjin Zhu
Link to Docket External link to docket
Small Molecule Drugs cited in Novartis AG v. Actavis Elizabeth LLC
The small molecule drug covered by the patent cited in this case is ➤ Sign Up .

Details for Novartis AG v. Actavis Elizabeth LLC (D. Del. 2014)

Date Filed Document No. Description Snippet Link To Document
2014-12-16 1 mg, prior to expiration of U.S. Patent No. 5,604,229 (“the ’229 patent”). ME1 19554697v.1 Case …. This is an action for patent infringement arising under the patent laws of the United States, … the U.S. Patent and Trademark Office duly and legally issued the ’229 patent, entitled…copy of the ’229 patent is attached hereto as Exhibit A. The claims of the ’229 patent are valid and enforceable…’229 patent in connection with GILENYA®. INFRINGEMENT BY ACTAVIS OF THE PATENT-IN-SUIT External link to document
2016-08-30 166 Coleman, Ph.D. on the Invalidity of U.S. Patent No. 5,604,229 filed by Actavis Elizabeth LLC, Actavis … 2014 9 June 2017 1:14-cv-01487 830 Patent None District Court, D. Delaware External link to document
2017-02-28 213 the Issue of Improper Inventorship of U.S. Patent No. 5,604,229 filed by Mitsubishi Tanabe Pharma Corporation… 2014 9 June 2017 1:14-cv-01487 830 Patent None District Court, D. Delaware External link to document
2017-03-28 253 Summary Judgment of Infringement on U.S. Patent No. 5,604,229, Claim 46 filed by Mitsubishi Tanabe Pharma… 2014 9 June 2017 1:14-cv-01487 830 Patent None District Court, D. Delaware External link to document
Date Filed Document No. Description Snippet Link To Document

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Teva
Argus Health
Daiichi Sankyo
Farmers Insurance
Medtronic
Federal Trade Commission
Colorcon
Cantor Fitzgerald
QuintilesIMS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.